VEGF RECEPTOR BURNS FOR THE TREATMENT OF EYE DISORDERS CHARACTERIZED BY VASCULAR PERMEABILITY.

摘要

Use of a fusion polypeptide that can bind to vascular endothelial growth factor (FCEV) in the manufacture of a medicament for treating an eye disorder characterized by vascular permeability, where the fusion polypeptide comprises: a) a receptor component of the FCEV, consisting essentially of the 2 immunoglobulinoid (Ig) domain of a first FCEV receptor and the 3 Ig domain of a second FCEV receptor; and b) a multimerization component; and where the first FCEV receptor is Flt1 and the second FCEV receptor is Flk1 or Flt4 and the FCEV receptor component is the only FCEV receptor component of the fusion polypeptide.